Nu:ionic Technologies and RW Energy Announce Strategic Alliance for Distributed Scale Hydrogen Production and CO2 Capture Projects
Globe Newswire29-08-2024, 18:30
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00
